Evidence map›Paper›PMID 23083438›Full record

SynthesisInternational psychogeriatrics2013

Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.

Dallas P Seitz, Sudeep S Gill, Nathan Herrmann, Sarah Brisbin, Mark J Rapoport, Jenna Rines, Kimberley Wilson, Ken Le Clair, David K Conn

Open access · diamondAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International psychogeriatrics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 120 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Dallas P SeitzDepartment of Psychiatry, Queen's University, Kingston, Ontario, Canada. seitzd@providencecare.ca
Sudeep S Gill
Nathan Herrmann
Sarah Brisbin
Mark J Rapoport
Jenna Rines
Kimberley Wilson
Ken Le Clair
David K Conn
Queen's University · CACanadian Mental Health Association · CAHealth Sciences Centre · CASunnybrook Health Science Centre · CAUniversity of Toronto · CA

Funding

Canadian Institutes of Health Research KRS#103345
6 · The paper itself

Abstract

backgroundMedications are frequently prescribed for neuropsychiatric symptoms (NPS) associated with dementia, although information on the efficacy and safety of medications for NPS specifically in long-term care (LTC) settings is limited. The objective of this study was to provide a current review of the efficacy and safety of pharmacological treatments for NPS in LTC.

methodsWe searched MEDLINE, EMBASE, PsychINFO, and the Cochrane Library for randomized controlled trials comparing medications with either placebo or other interventions in LTC. Study quality was described using the Cochrane collaboration risk of bias tool. The efficacy of medications was evaluated using NPS symptom rating scales. Safety was evaluated through rates of trial withdrawals, trial withdrawals due to adverse events, and mortality.

resultsA total of 29 studies met inclusion criteria. The most common medications evaluated in studies were atypical antipsychotics (N = 15), typical antipsychotics (N = 7), anticonvulsants (N = 4), and cholinesterase inhibitors (N = 3). Statistically significant improvements in NPS were noted in some studies evaluating risperidone, olanzapine, and single studies of aripiprazole, carbamazepine, estrogen, cyproterone, propranolol, and prazosin. Study quality was difficult to rate in many cases due to incomplete reporting of details. Some studies reported higher rates of trial withdrawals, adverse events, and mortality associated with medications.

conclusionsWe conclude that there is limited evidence to support the use of some atypical antipsychotics and other medications for NPS in LTC populations. However, the generally modest efficacy and risks of adverse events highlight the need for the development of safe and effective pharmacological and non-pharmacological interventions for this population.

Indexed as

AnticonvulsantsAntidepressive AgentsAntipsychotic AgentsCholinesterase InhibitorsBehavioral SymptomsDementiaDiagnostic Techniques, NeurologicalHumansLong-Term CarePractice Patterns, Physicians'Psychiatric Status Rating ScalesPsychomotor DisordersRandomized Controlled Trials as TopicTreatment OutcomeAnticonvulsantsAntidepressive AgentsAntipsychotic AgentsCholinesterase Inhibitors

Identifiers

PMID23083438
PMCPMC3544545
OpenAlexW2063426571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.